CPLB said that the new facility utilises equipment for fast and efficient production of up to potentially 60 million doses of novel vaccines every year.
The facility plans to produce seasonal and pandemic flu vaccines based on Novavax’s advanced virus-like particle (VLP) technology which enables the rapid development and production of novel vaccines without the use of live virus.
IA Modi, chairman of Cadila Pharmaceuticals, said: “This facility demonstrates our commitment to establishing the highest-quality vaccine production facility for our nation. It utilises design and equipment that will be competitive with the world’s leading vaccine companies.”
Rahul Singhvi, president and CEO of Novavax, said: “We congratulate our colleagues at CPL Biologicals on reaching this important milestone in the development of a vaccine production facility.
“This achievement reflects our strategy to partner with pharmaceutical companies around the world to develop, in-country vaccine-production capacity and use our novel vaccine technology to solve critical public health problems.
“This world class vaccine production plant in India will be able to supply India and other countries with novel vaccines against influenza and other infectious diseases by using an efficient, reliable and flexible vaccine production process.”